Kadmon Holdings Revenue and Competitors
Estimated Revenue & Valuation
- Kadmon Holdings's estimated annual revenue is currently $5.7M per year.
- Kadmon Holdings received $Undisclosed in venture funding in June 2018.
- Kadmon Holdings's estimated revenue per employee is $77,500
- Kadmon Holdings's total funding is $629.5M.
- Kadmon Holdings's current valuation is $1.7B. (November 2021)
Employee Data
- Kadmon Holdings has 73 Employees.
- Kadmon Holdings grew their employee count by -17% last year.
Kadmon Holdings's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate VP, Marketing | Reveal Email/Phone |
2 | SVP, Head Chemistry | Reveal Email/Phone |
3 | VP Sales Bone Marrow Transplant | Reveal Email/Phone |
4 | SVP, Commercial Finance | Reveal Email/Phone |
5 | SVP, Clinical Sciences | Reveal Email/Phone |
6 | SVP, Human Resources | Reveal Email/Phone |
7 | Director, Quality Assurance | Reveal Email/Phone |
8 | Senior Director, Enterprise Transformation | Reveal Email/Phone |
9 | Regional Business Director | Reveal Email/Phone |
10 | associate director | Reveal Email/Phone |
Kadmon Holdings Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 4 | -20% | N/A | N/A |
#2 | $6.7M | 43 | 8% | N/A | N/A |
#3 | $34.4M | 222 | -1% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.3M | 2 | -50% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $3.6M | 23 | 0% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is Kadmon Holdings?
Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing our small molecule and biologics platforms. We utilize our advanced understanding of the molecular mechanisms of disease to establish development paths for disease areas where significant unmet medical needs exist.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$629.5M
Total Funding
73
Number of Employees
$5.7M
Revenue (est)
-17%
Employee Growth %
$1.7B
Valuation
N/A
Accelerator
Kadmon Holdings News
Sanofi gained rights to Rezurock along with its $1.9 billion acquisition of Kadmon Holdings last year. The pooled analysis of the ROCKstar...
Kadmon Holdings; Diapath; Leica Biosystems Nussloch; Genta Environmental; Carl Roth; Magnacol; Serosep; Thermo Fisher Scientific. ACCESS FULL...
Six months after acquiring Kadmon Holdings, pharma giant Sanofi is closing the company's New York facility. As part of the paring down,...
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.5M | 73 | -35% | N/A |
#2 | $13.5M | 73 | -30% | N/A |
#3 | $9.5M | 73 | -35% | N/A |
#4 | $16.4M | 73 | -15% | N/A |
#5 | $320.2M | 73 | 6% | N/A |
Kadmon Holdings Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2017-03-09 | $23.0M | Undisclosed | Jefferies LLC | Article |
| 2017-09-29 | $80.4M | Undisclosed | Vivo Capital | Article |
| 2018-06-12 | $Undisclosed | Undisclosed | Jefferies LLC | Article |